Page last updated: 2024-09-04

levofloxacin and clonazepam

levofloxacin has been researched along with clonazepam in 5 studies

Compound Research Comparison

Studies
(levofloxacin)
Trials
(levofloxacin)
Recent Studies (post-2010)
(levofloxacin)
Studies
(clonazepam)
Trials
(clonazepam)
Recent Studies (post-2010) (clonazepam)
4,3465812,2092,719239519

Protein Interaction Comparison

ProteinTaxonomylevofloxacin (IC50)clonazepam (IC50)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)0.0017
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)0.0017
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)0.0017
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)0.0017
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)0.0017
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)0.0017
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)0.0017
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)0.0017
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)0.0017
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)0.0017
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)0.0017
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)0.0017
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)0.0017
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)0.0017
GABA theta subunitRattus norvegicus (Norway rat)0.0017
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)0.0017

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1

Reviews

1 review(s) available for levofloxacin and clonazepam

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for levofloxacin and clonazepam

ArticleYear
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010